Last reviewed 2026-04-22 · How we verify

Ceftriaxone for Injection

Ceftriaxone for Injection is a Third-generation cephalosporin Small molecule drug developed by The University of Queensland. It is currently FDA-approved for Bacterial infections including lower respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, meningitis, and gonorrhea, Surgical prophylaxis. Also known as: Rocephin.

Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking cross-linking of peptidoglycan.

Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking cross-linking of peptidoglycan. Used for Bacterial infections including lower respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, meningitis, and gonorrhea, Surgical prophylaxis.

At a glance

Mechanism of action

Ceftriaxone is a third-generation cephalosporin antibiotic that penetrates bacterial cell walls and irreversibly binds to penicillin-binding proteins, preventing the cross-linking of peptidoglycan strands essential for cell wall integrity. This leads to cell wall weakening, osmotic instability, and bacterial cell lysis. It is bactericidal and has broad-spectrum activity against gram-positive and gram-negative bacteria.

Approved indications

• Bacterial infections including lower respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, meningitis, and gonorrhea
• Surgical prophylaxis

Common side effects

• Diarrhea
• Nausea
• Rash
• Phlebitis at injection site
• Hypersensitivity reactions

Key clinical trials

• Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
• Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
• Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) (PHASE4)
• To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia (PHASE2)
• Paramedic Initiated Treatment of Sepsis Targeting Out-of-hospital Patients (PITSTOP) (PHASE4)
• Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients (PHASE3)
• Parenteral Versus Combined Parenteral With Vancomycin-soaked Graft in ACL Reconstruction (NA)
• Trial Comparing Ceftriaxone Plus Azithromycin Versus Ceftriaxone for the Treatment of Gonorrhea (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Ceftriaxone for Injection CI brief — competitive landscape report
• Ceftriaxone for Injection updates RSS · CI watch RSS
• The University of Queensland portfolio CI

Frequently asked questions about Ceftriaxone for Injection

Related

• Drug class: All Third-generation cephalosporin drugs
• Target: All drugs targeting Penicillin-binding proteins (PBPs)
• Manufacturer: The University of Queensland — full pipeline
• Therapeutic area: All drugs in Infectious Disease
• Indication: Drugs for Bacterial infections including lower respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, meningitis, and gonorrhea
• Indication: Drugs for Surgical prophylaxis
• Also known as: Rocephin

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing